{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:05:22Z","timestamp":1774469122777,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Prim. Care Respir. Med."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Older patients with chronic obstructive pulmonary disease (COPD) may be at increased risk of adverse events (AEs) due to decreased protective organ function and increased comorbidities. TONADO\u00ae 1\u2009+\u20092 were replicate, randomized, double-blind, parallel-group, 52-week, Phase III trials comparing the efficacy and safety of tiotropium\/olodaterol (5\/5\u2009\u00b5g) versus the monocomponents via the Respimat\u00ae inhaler in patients with moderate-to-very-severe COPD. In this prespecified safety analysis, patients were grouped by age. Of 3100 patients, 1585 (51.1%) were aged &lt;65 years, 1198 (38.7%) 65\u2013&lt;75 years, 309 (10.0%) 75\u2013&lt;85 years, and eight (0.3%) \u226585 years. At baseline, 23.4% had a pre-existing cardiac disorder, 45.6% had hypertension, and 13.3% had glucose metabolism disorders, including diagnosed diabetes. Overall, there was no increase in major adverse cardiac events, other AEs, or serious AEs with tiotropium\/olodaterol versus the monocomponents in any age group, supporting the safety of tiotropium\/olodaterol in older patients with COPD.<\/jats:p>","DOI":"10.1038\/s41533-020-00212-w","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T11:06:08Z","timestamp":1607079968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term safety of tiotropium\/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO\u00ae studies"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3277-4110","authenticated-orcid":false,"given":"Gary T.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Maltais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Karpel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6515-0841","authenticated-orcid":false,"given":"Ulrich","family":"Bothner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Kloer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Trampisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"212_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 Report). https:\/\/goldcopd.org\/wp-content\/uploads\/2019\/11\/GOLD-2020-REPORT-ver1.0wms.pdf (2019)."},{"key":"212_CR2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1164\/ajrccm.164.4.2003167","volume":"164","author":"TL Feenstra","year":"2001","unstructured":"Feenstra, T. L., van Genugten, M. L., Hoogenveen, R. T., Wouters, E. F. & Rutten-van Molken, M. P. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am. J. Respir. Crit. Care Med. 164, 590\u2013596 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"212_CR3","unstructured":"World Health Organization. Chronic Respiratory Diseases. http:\/\/www.who.int\/respiratory\/en\/ (WHO, 2019)."},{"key":"212_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2147\/COPD.S61717","volume":"9","author":"GT Ferguson","year":"2014","unstructured":"Ferguson, G. T. et al. Efficacy and safety of olodaterol once daily delivered via Respimat\u00ae in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int. J. Chron. Obstruct. Pulmon. Dis. 9, 629\u2013645 (2014).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"212_CR5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3109\/15412555.2014.991864","volume":"12","author":"L McGarvey","year":"2015","unstructured":"McGarvey, L. et al. One-year safety of olodaterol once daily via Respimat\u00ae in patients with GOLD 2-4 chronic obstructive pulmonary disease: results of a pre-specified pooled analysis. COPD 12, 484\u2013493 (2015).","journal-title":"COPD"},{"key":"212_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl, R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2\u20134). Eur. Respir. J. 45, 969\u2013979 (2015).","journal-title":"Eur. Respir. J."},{"key":"212_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1183\/09031936.06.00124605","volume":"28","author":"RJ Halbert","year":"2006","unstructured":"Halbert, R. J. et al. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 28, 523\u2013532 (2006).","journal-title":"Eur. Respir. J."},{"key":"212_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/ciia.2006.1.3.253","volume":"1","author":"G Sharma","year":"2006","unstructured":"Sharma, G. & Goodwin, J. Effect of aging on respiratory system physiology and immunology. Clin. Interv. Aging 1, 253\u2013260 (2006).","journal-title":"Clin. Interv. Aging"},{"key":"212_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.pupt.2005.08.004","volume":"19","author":"V Bellia","year":"2006","unstructured":"Bellia, V., Battaglia, S., Matera, M. G. & Cazzola, M. The use of bronchodilators in the treatment of airway obstruction in elderly patients. Pulm. Pharmacol. Ther. 19, 311\u2013319 (2006).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"212_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1055\/s-0030-1265900","volume":"31","author":"NA Hanania","year":"2010","unstructured":"Hanania, N. A., Sharma, G. & Sharafkhaneh, A. COPD in the elderly patient. Semin. Respir. Crit. Care Med. 31, 596\u2013606 (2010).","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"212_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ageing\/afj002","volume":"35","author":"J Yeo","year":"2006","unstructured":"Yeo, J., Karimova, G. & Bansal, S. Co-morbidity in older patients with COPD \u2013 its impact on health service utilisation and quality of life, a community study. Age Ageing 35, 33\u201337 (2006).","journal-title":"Age Ageing"},{"key":"212_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1183\/09059180.00003609","volume":"18","author":"C Raherison","year":"2009","unstructured":"Raherison, C. & Girodet, P. O. Epidemiology of COPD. Eur. Respir. Rev. 18, 213\u2013221 (2009).","journal-title":"Eur. Respir. Rev."},{"key":"212_CR13","unstructured":"Boehringer Ingelheim Limited. Striverdi Respimat 2.5 Microgram, Solution for Inhalation. https:\/\/www.medicines.org.uk\/emc\/medicine\/28992 (2016)."},{"key":"212_CR14","unstructured":"Boehringer Ingelheim International GmbH. Spiolto Respimat 2.5 Microgram\/2.5 Microgram, Inhalation Solution \u2013 Summary of Product Characteristics, Labelling and Package Leaflet 2015. http:\/\/mri.medagencies.org\/download\/NL_H_3157_001_FinalPI.pdf (2016)."},{"key":"212_CR15","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. SPIRIVA\u00ae RESPIMAT\u00ae (Tiotropium Bromide) Inhalation Spray, for Oral Inhalation. http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Spiriva%20Respimat\/spirivarespimat.pdf (2017)."},{"key":"212_CR16","doi-asserted-by":"crossref","unstructured":"Nici, L. et al. Pharmacologic management of COPD: an official American Thoracic Society clinical practice guideline. Am. J. Respir. Crit. Care Med. 201, e56\u2013e69 (2020).","DOI":"10.1164\/rccm.202003-0625ST"},{"key":"212_CR17","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2147\/COPD.S108758","volume":"11","author":"GT Ferguson","year":"2016","unstructured":"Ferguson, G. T. et al. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO\u00ae and OTEMTO\u00ae studies: a subgroup analysis by age. Int. J. Chron. Obstruct. Pulmon. Dis. 11, 2701\u20132710 (2016).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"212_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.rmed.2016.11.011","volume":"122","author":"R Buhl","year":"2017","unstructured":"Buhl, R. et al. Long-term general and cardiovascular safety of tiotropium\/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respir. Med. 122, 58\u201366 (2017).","journal-title":"Respir. Med."},{"key":"212_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.rmed.2018.08.012","volume":"143","author":"GT Ferguson","year":"2018","unstructured":"Ferguson, G. T. et al. Safety of tiotropium\/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respir. Med. 143, 67\u201373 (2018).","journal-title":"Respir. Med."},{"key":"212_CR20","doi-asserted-by":"publisher","first-page":"020415","DOI":"10.7189\/jogh.05.020415","volume":"5","author":"D Adeloye","year":"2015","unstructured":"Adeloye, D. et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J. Glob. Health 5, 020415 (2015).","journal-title":"J. Glob. Health"},{"key":"212_CR21","unstructured":"World Health Organization. Burden of COPD. http:\/\/www.who.int\/respiratory\/copd\/burden\/en\/ (WHO, 2019)."},{"key":"212_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1465-9921-14-40","volume":"14","author":"RA Wise","year":"2013","unstructured":"Wise, R. A. et al. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir. Res. 14, 40 (2013).","journal-title":"Respir. Res."},{"key":"212_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/gerona\/glr251","volume":"67","author":"KM Akgun","year":"2012","unstructured":"Akgun, K. M., Crothers, K. & Pisani, M. Epidemiology and management of common pulmonary diseases in older persons. J. Gerontol. A Biol. Sci. Med. Sci. 67, 276\u2013291 (2012).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"212_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1513\/pats.200709-148ET","volume":"5","author":"WM Chatila","year":"2008","unstructured":"Chatila, W. M., Thomashow, B. M., Minai, O. A., Criner, G. J. & Make, B. J. Comorbidities in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 5, 549\u2013555 (2008).","journal-title":"Proc. Am. Thorac. Soc."},{"key":"212_CR25","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.chest.2018.01.008","volume":"153","author":"F Maltais","year":"2018","unstructured":"Maltais, F. et al. Beta-blockers in COPD: a cohort study from the TONADO research program. Chest 153, 1315\u20131325 (2018).","journal-title":"Chest"},{"key":"212_CR26","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.chest.2018.01.032","volume":"153","author":"M Cazzola","year":"2018","unstructured":"Cazzola, M. & Matera, M. G. Combining dual bronchodilation and \u03b2-blockade in patients with an overlap between COPD and cardiovascular diseases. Chest 153, 1289\u20131291 (2018).","journal-title":"Chest"},{"key":"212_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s40749-015-0013-y","volume":"1","author":"L Puente-Maestu","year":"2015","unstructured":"Puente-Maestu, L., \u00c1lvarez-Sala, L. A. & de Miguel-D\u00edez, J. Beta-blockers in patients with chronic obstructive disease and coexistent cardiac illnesses. COPD Res. Pract. 1, 11 (2015).","journal-title":"COPD Res. Pract."},{"key":"212_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cger.2010.08.006","volume":"27","author":"NS Fedarko","year":"2011","unstructured":"Fedarko, N. S. The biology of aging and frailty. Clin. Geriatr. Med. 27, 27\u201337 (2011).","journal-title":"Clin. Geriatr. Med."},{"key":"212_CR29","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.2147\/COPD.S161489","volume":"2018","author":"C LaForce","year":"2018","unstructured":"LaForce, C. et al. Long-term safety of tiotropium\/olodaterol Respimat\u00ae in patients with moderate-to-very severe COPD and renal impairment in the TONADO\u00ae studies. Int. J. Chron. Obstruct. Pulmon. Dis. 2018, 1819\u20131831 (2018).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"212_CR30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40262-014-0143-4","volume":"53","author":"N Goyal","year":"2014","unstructured":"Goyal, N. et al. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease. Clin. Pharmacokinet. 53, 637\u2013648 (2014).","journal-title":"Clin. Pharmacokinet."},{"key":"212_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s13318-015-0303-4","volume":"41","author":"S Siederer","year":"2016","unstructured":"Siederer, S., Allen, A. & Yang, S. Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in subjects with chronic obstructive pulmonary disease. Eur. J. Drug Metab. Pharmacokinet. 41, 743\u2013758 (2016).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"212_CR32","unstructured":"Boehringer Ingelheim International GmbH. Striverdi Respimat 2.5 Microgram, Solution for Inhalation \u2013 Summary of Product Characteristics, Europe. https:\/\/www.medicines.org.uk\/emc\/product\/3255\/smpc (2019)."},{"key":"212_CR33","unstructured":"Novartis Pharmaceuticals UK Ltd. Seebri Breezhaler Inhalation Powder, Hard Capsules 44mcg \u2013 Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/27138\/SPC\/Seebri+Breezhaler+Inhalation+Powder,+Hard+Capsules+44mcg\/ (2016)."},{"key":"212_CR34","unstructured":"GlaxoSmithKline UK. Relvar Ellipta 184 Micrograms\/22 Micrograms Inhalation Powder, Pre-Dispensed. https:\/\/www.medicines.org.uk\/emc\/product\/5225\/smpc (2017)."},{"key":"212_CR35","unstructured":"AstraZeneca UK Limited. Duaklir Genuair 340 Micrograms\/12 Micrograms Inhalation Powder \u2013 Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/29652 (2017)."},{"key":"212_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1378\/chest.108.2.401","volume":"108","author":"MJ Connolly","year":"1995","unstructured":"Connolly, M. J., Crowley, J. J., Charan, N. B., Nielson, C. P. & Vestal, R. E. Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest 108, 401\u2013406 (1995).","journal-title":"Chest"},{"key":"212_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3892\/etm.2013.956","volume":"5","author":"H Satoh","year":"2013","unstructured":"Satoh, H. et al. Use of tiotropium in patients with COPD aged 80 years and older. Exp. Ther. Med. 5, 997\u20131000 (2013).","journal-title":"Exp. Ther. Med."},{"key":"212_CR38","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/00325481.2017.1317575","volume":"129","author":"NA Hanania","year":"2017","unstructured":"Hanania, N. A., Lareau, S. C. & Yawn, B. P. Safety of inhaled long-acting anti-muscarinic agents in COPD. Postgrad. Med. 129, 500\u2013512 (2017).","journal-title":"Postgrad. Med."}],"container-title":["npj Primary Care Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41533-020-00212-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-020-00212-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-020-00212-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:30:02Z","timestamp":1670293802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41533-020-00212-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1038\/s41533-020-00212-w","relation":{},"ISSN":["2055-1010"],"issn-type":[{"value":"2055-1010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]},"assertion":[{"value":"14 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.T.F. has received grants, personal fees, and non-financial support from Boehringer Ingelheim, Novartis, AstraZeneca, Pearl Therapeutics, and Sunovion; grants and personal fees from Theravance; and personal fees from Verona, Mylan, Innoviva, GlaxoSmithKline, and Circassia outside the submitted work. F.M. received fees for speaking at conferences sponsored by Boehringer Ingelheim, Novartis, and Grifols; research grants for participating in multicenter trials sponsored by GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Novartis; and unrestricted research grants from Boehringer Ingelheim, Novartis, and Grifols. He also holds a CIHR\/GlaxoSmithKline research chair on COPD. J.K. has nothing to disclose. U.B., I.K., and M.T. are employees of Boehringer Ingelheim. R.B. has received grants and personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche; and personal fees from AstraZeneca, Chiesi, Cipla, and Teva. The authors received no compensation related to the development of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}